Blarcamesine Shows Promise in Parkinson’s Disease Dementia Trial
Anavex Life Sciences recently announced encouraging results from a long-term extension of their Phase 2 trial involving ANAVEX2-73, also known as blarcamesine, aimed at treating Parkinson’s disease dementia (PDD). This trial, designated as ANAVEX2-73-PDD-EP-001, spanned 48 weeks and provided significant insights into the potential efficacy and safety of the investigational agent. During the open-label extension (OLE), patients who continued with […]
